Citadel Advisors
RNAZ icon

Citadel Advisors’s TransCode Therapeutics RNAZ Stock Holding History

Citadel Advisors’s Portfolio RNAZ Stock Details RNAZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-28
Closed -$25.6K – 15084
2024
Q2 		$25.6K Buy
+28
New +$24.9K ﹤0.01% 12420
2024
Q1 		– Sell
-8
Closed -$46.5K – 15332
2023
Q4 		$46.5K Buy
+8
New +$90K ﹤0.01% 11852
2021
Q4 		– Hold
0
– -$271K – 14606
2021
Q3 		– Hold
0
– – – 11281

Other funds holding RNAZ

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
SSWM
Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $41.5B AUM 29.19% 1-Year Est. Return

Citadel Advisors's RNAZ Position: Q3 2024 in Review

Citadel Advisors sold out of TransCode Therapeutics (RNAZ) in Q3 2024, closing a stake of 28 shares — an estimated $25.6K sold.

Citadel Advisors first reported a position in RNAZ in Q4 2023 and held it in 2 quarters. The position peaked at $46.5K in Q4 2023. 7 funds tracked by Wall St. Rank hold RNAZ as of Q3 2024.

  • Citadel Advisors reported no remaining TransCode Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 28 TransCode Therapeutics shares in Q3 2024, an estimated $25.6K.
  • Citadel Advisors first reported a position in TransCode Therapeutics in Q4 2023 and held it in 2 quarters.
  • Citadel Advisors's TransCode Therapeutics position peaked at $46.5K in Q4 2023.
  • 7 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.